米氮平与氟西汀治疗抑郁症临床对照研究

The clinical control study of mirtazapine and froxitin in depression

目的米氮平与氟西汀治疗抑郁症的有效性和安全性。方法将符合CCMD-Ⅲ抑郁症诊断标准的75例患者随机分为两组,分别给予米氮平及氟西汀治疗,并观察6周,采用汉密尔顿抑郁量表(HAMD)、临床总体印象量表(CGI)、不良反应症状量表(TESS)进行评分。结果两组有效率分别为86.84%和82.86%。两者无差异(P>0.05)。结论米氮平治疗抑郁症总体疗效与氟西汀相当,但其起效快,不良反应较轻,耐受性好。

Objective To compare the effect and safety between miltazapine and froxitin in depression. Methods 75 Patients with deprssion who meet diagnostic criteris of CCMD -Ⅲ were divided into two groups and were treated with mirtazapine and froxitin for 6 week. All patients were assessed with Hamilton rating scale for depression (HAMD) , clinical grobal impressions Scale (CGI) and Treatment emergent symptoms scale (TESS) . Results The effect in patients with mirtazapine and with froxitin were not significa-nty different( 86. 84% ,82.86% ; P>0.05). Conclusion The effect in depressions patients with mirtazapine were as with froxitin. Compare with froxitin, mirtazapine was more effect - rapidness , less treatment emergent symptoms and high toleration.